| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 65 | 2020 | 355 | 16.790 |
Why?
|
| Brain Neoplasms | 78 | 2020 | 637 | 16.370 |
Why?
|
| Meningioma | 11 | 2020 | 59 | 3.330 |
Why?
|
| Glioblastoma | 13 | 2020 | 159 | 3.210 |
Why?
|
| Cranial Irradiation | 14 | 2020 | 94 | 3.090 |
Why?
|
| Salvage Therapy | 17 | 2020 | 135 | 2.800 |
Why?
|
| Middle Aged | 84 | 2020 | 11851 | 2.480 |
Why?
|
| Trigeminal Neuralgia | 8 | 2019 | 33 | 2.450 |
Why?
|
| Neoplasm Recurrence, Local | 16 | 2020 | 381 | 2.440 |
Why?
|
| Retrospective Studies | 51 | 2020 | 3626 | 2.360 |
Why?
|
| Treatment Outcome | 45 | 2020 | 3416 | 2.280 |
Why?
|
| Glioma | 12 | 2020 | 137 | 2.160 |
Why?
|
| Aged | 65 | 2020 | 10263 | 2.130 |
Why?
|
| Lung Neoplasms | 15 | 2020 | 423 | 2.090 |
Why?
|
| Female | 94 | 2020 | 19945 | 2.020 |
Why?
|
| Meningeal Neoplasms | 8 | 2020 | 49 | 2.000 |
Why?
|
| Humans | 124 | 2020 | 32282 | 1.970 |
Why?
|
| Radiotherapy | 7 | 2019 | 92 | 1.970 |
Why?
|
| Male | 85 | 2020 | 19441 | 1.910 |
Why?
|
| Adult | 58 | 2020 | 9259 | 1.700 |
Why?
|
| Aged, 80 and over | 35 | 2020 | 3900 | 1.670 |
Why?
|
| Melanoma | 9 | 2019 | 166 | 1.500 |
Why?
|
| Follow-Up Studies | 28 | 2020 | 2240 | 1.460 |
Why?
|
| Multiple Sclerosis | 3 | 2019 | 62 | 1.270 |
Why?
|
| Prognosis | 14 | 2020 | 1534 | 1.240 |
Why?
|
| Neoplasms | 6 | 2020 | 754 | 1.190 |
Why?
|
| Nomograms | 4 | 2017 | 35 | 1.060 |
Why?
|
| Survival Analysis | 13 | 2020 | 477 | 0.980 |
Why?
|
| Breast Neoplasms | 11 | 2019 | 762 | 0.980 |
Why?
|
| Survival Rate | 12 | 2020 | 893 | 0.950 |
Why?
|
| Intracranial Arteriovenous Malformations | 4 | 2019 | 19 | 0.880 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2020 | 1224 | 0.880 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2018 | 45 | 0.850 |
Why?
|
| Adenocarcinoma | 4 | 2019 | 298 | 0.840 |
Why?
|
| Radiotherapy Dosage | 13 | 2017 | 107 | 0.840 |
Why?
|
| Cognition Disorders | 4 | 2015 | 349 | 0.830 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2019 | 108 | 0.830 |
Why?
|
| Neoplasm Metastasis | 7 | 2020 | 222 | 0.800 |
Why?
|
| Postoperative Complications | 6 | 2019 | 823 | 0.790 |
Why?
|
| Genomics | 3 | 2018 | 89 | 0.760 |
Why?
|
| Radiation Injuries | 7 | 2016 | 85 | 0.750 |
Why?
|
| Disease Progression | 7 | 2020 | 591 | 0.740 |
Why?
|
| Young Adult | 18 | 2020 | 2649 | 0.730 |
Why?
|
| Treatment Failure | 10 | 2020 | 165 | 0.680 |
Why?
|
| Disease-Free Survival | 11 | 2020 | 324 | 0.650 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2017 | 86 | 0.640 |
Why?
|
| Astrocytoma | 2 | 2018 | 28 | 0.640 |
Why?
|
| Carcinoma | 1 | 2020 | 92 | 0.610 |
Why?
|
| Pineal Gland | 1 | 2018 | 2 | 0.580 |
Why?
|
| Combined Modality Therapy | 9 | 2018 | 555 | 0.580 |
Why?
|
| Brain | 8 | 2019 | 965 | 0.570 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 106 | 0.560 |
Why?
|
| Adolescent | 11 | 2020 | 3519 | 0.550 |
Why?
|
| Small Cell Lung Carcinoma | 4 | 2020 | 17 | 0.520 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 186 | 0.520 |
Why?
|
| Nervous System Neoplasms | 1 | 2017 | 8 | 0.510 |
Why?
|
| Medicare | 1 | 2018 | 219 | 0.510 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 34 | 0.500 |
Why?
|
| Cerebellar Neoplasms | 2 | 2019 | 11 | 0.470 |
Why?
|
| Brain Edema | 2 | 2014 | 16 | 0.460 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2012 | 34 | 0.460 |
Why?
|
| Ganglioglioma | 1 | 2015 | 6 | 0.450 |
Why?
|
| Central Nervous System Diseases | 1 | 2015 | 17 | 0.450 |
Why?
|
| Benzhydryl Compounds | 1 | 2015 | 23 | 0.450 |
Why?
|
| Neurofibromatosis 2 | 1 | 2015 | 5 | 0.440 |
Why?
|
| Fatigue | 1 | 2015 | 76 | 0.440 |
Why?
|
| Choroid Neoplasms | 2 | 2011 | 4 | 0.430 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2014 | 7 | 0.430 |
Why?
|
| Incidence | 4 | 2020 | 1241 | 0.420 |
Why?
|
| Proportional Hazards Models | 5 | 2019 | 773 | 0.420 |
Why?
|
| Brain Stem Neoplasms | 1 | 2014 | 4 | 0.420 |
Why?
|
| Pain Measurement | 3 | 2014 | 341 | 0.420 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2014 | 907 | 0.410 |
Why?
|
| Carcinoma, Small Cell | 1 | 2013 | 21 | 0.400 |
Why?
|
| Smoking | 1 | 2017 | 505 | 0.390 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 157 | 0.390 |
Why?
|
| Visual Acuity | 3 | 2014 | 76 | 0.390 |
Why?
|
| Risk Factors | 7 | 2019 | 3934 | 0.390 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2012 | 3 | 0.370 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2012 | 27 | 0.370 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 541 | 0.370 |
Why?
|
| Ependymoma | 1 | 2012 | 4 | 0.360 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2012 | 65 | 0.360 |
Why?
|
| Vision Disorders | 1 | 2011 | 23 | 0.350 |
Why?
|
| Child | 7 | 2020 | 2435 | 0.350 |
Why?
|
| Antineoplastic Agents | 6 | 2018 | 595 | 0.350 |
Why?
|
| Neoplastic Stem Cells | 4 | 2020 | 96 | 0.350 |
Why?
|
| Time Factors | 6 | 2017 | 2205 | 0.350 |
Why?
|
| Collagen Diseases | 1 | 2011 | 5 | 0.350 |
Why?
|
| Tumor Burden | 5 | 2014 | 63 | 0.340 |
Why?
|
| Cell Line, Tumor | 12 | 2020 | 729 | 0.330 |
Why?
|
| Radiation Dosage | 3 | 2020 | 91 | 0.330 |
Why?
|
| Medulloblastoma | 1 | 2010 | 8 | 0.330 |
Why?
|
| Vascular Diseases | 1 | 2011 | 66 | 0.330 |
Why?
|
| Cohort Studies | 5 | 2019 | 1840 | 0.320 |
Why?
|
| Prospective Studies | 8 | 2019 | 2316 | 0.320 |
Why?
|
| Brachytherapy | 1 | 2010 | 31 | 0.320 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2015 | 83 | 0.320 |
Why?
|
| Radiation Oncology | 1 | 2010 | 14 | 0.320 |
Why?
|
| Lymphoma | 1 | 2010 | 37 | 0.310 |
Why?
|
| Catheter Ablation | 1 | 2010 | 113 | 0.300 |
Why?
|
| Facial Pain | 3 | 2014 | 21 | 0.290 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2015 | 36 | 0.290 |
Why?
|
| Microglia | 2 | 2020 | 67 | 0.290 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2020 | 232 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2018 | 19 | 0.260 |
Why?
|
| Databases, Factual | 2 | 2020 | 368 | 0.260 |
Why?
|
| Neoplasm Staging | 3 | 2015 | 461 | 0.260 |
Why?
|
| Radiotherapy, Conformal | 2 | 2018 | 18 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 443 | 0.250 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2014 | 30 | 0.250 |
Why?
|
| Signal Transduction | 4 | 2020 | 727 | 0.250 |
Why?
|
| Multivariate Analysis | 4 | 2014 | 651 | 0.230 |
Why?
|
| Brain Death | 2 | 2017 | 23 | 0.220 |
Why?
|
| Mice | 10 | 2020 | 2571 | 0.220 |
Why?
|
| Lymphatic Metastasis | 3 | 2019 | 168 | 0.210 |
Why?
|
| Child, Preschool | 3 | 2020 | 1233 | 0.210 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 312 | 0.200 |
Why?
|
| DNA Methylation | 2 | 2015 | 144 | 0.200 |
Why?
|
| Cause of Death | 2 | 2015 | 236 | 0.200 |
Why?
|
| Quality of Life | 3 | 2019 | 964 | 0.200 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2017 | 113 | 0.200 |
Why?
|
| Animals | 14 | 2020 | 8199 | 0.200 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 258 | 0.190 |
Why?
|
| Kidney Neoplasms | 2 | 2017 | 200 | 0.180 |
Why?
|
| Neuropsychological Tests | 4 | 2019 | 327 | 0.180 |
Why?
|
| Recurrence | 4 | 2019 | 285 | 0.180 |
Why?
|
| Electromagnetic Fields | 2 | 2019 | 26 | 0.170 |
Why?
|
| Antigens, Neoplasm | 2 | 2019 | 39 | 0.170 |
Why?
|
| Receptor, erbB-2 | 3 | 2020 | 63 | 0.170 |
Why?
|
| Janus Kinase 2 | 1 | 2020 | 6 | 0.160 |
Why?
|
| Mice, Nude | 5 | 2020 | 285 | 0.160 |
Why?
|
| Analysis of Variance | 3 | 2017 | 471 | 0.160 |
Why?
|
| Immunity, Innate | 1 | 2020 | 82 | 0.160 |
Why?
|
| Plasma Cells | 1 | 2019 | 12 | 0.150 |
Why?
|
| Syndecan-1 | 1 | 2019 | 20 | 0.150 |
Why?
|
| Risk | 1 | 2020 | 305 | 0.150 |
Why?
|
| Magnetic Field Therapy | 1 | 2019 | 15 | 0.150 |
Why?
|
| Cystatin A | 1 | 2019 | 7 | 0.150 |
Why?
|
| Oligodendroglioma | 1 | 2019 | 2 | 0.150 |
Why?
|
| Hemangioblastoma | 1 | 2019 | 4 | 0.150 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2019 | 10 | 0.150 |
Why?
|
| Calcium Channels, T-Type | 1 | 2019 | 28 | 0.150 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2019 | 5 | 0.150 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2018 | 6 | 0.140 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 18 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 62 | 0.140 |
Why?
|
| Retreatment | 2 | 2016 | 42 | 0.140 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2018 | 62 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2018 | 95 | 0.140 |
Why?
|
| Protons | 1 | 2018 | 22 | 0.140 |
Why?
|
| Transcription Factors | 1 | 2019 | 183 | 0.140 |
Why?
|
| Nicotine | 1 | 2020 | 164 | 0.140 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 37 | 0.140 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2018 | 93 | 0.140 |
Why?
|
| Neovascularization, Pathologic | 3 | 2016 | 75 | 0.140 |
Why?
|
| Disease Management | 1 | 2019 | 129 | 0.140 |
Why?
|
| Exosomes | 1 | 2018 | 43 | 0.130 |
Why?
|
| Dacarbazine | 2 | 2016 | 31 | 0.130 |
Why?
|
| Glomus Jugulare Tumor | 1 | 2017 | 4 | 0.130 |
Why?
|
| Calcium | 1 | 2019 | 339 | 0.130 |
Why?
|
| Hearing Tests | 1 | 2017 | 12 | 0.130 |
Why?
|
| Double-Blind Method | 2 | 2015 | 565 | 0.130 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 117 | 0.130 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2016 | 25 | 0.120 |
Why?
|
| Confidence Intervals | 1 | 2017 | 141 | 0.120 |
Why?
|
| Interferon-Stimulated Gene Factor 3, gamma Subunit | 1 | 2016 | 2 | 0.120 |
Why?
|
| Sulfides | 1 | 2016 | 27 | 0.120 |
Why?
|
| Caprylates | 1 | 2016 | 27 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2018 | 181 | 0.120 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 49 | 0.120 |
Why?
|
| Survivors | 2 | 2018 | 173 | 0.120 |
Why?
|
| Cell Proliferation | 4 | 2019 | 603 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 180 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2018 | 189 | 0.120 |
Why?
|
| DNA Modification Methylases | 1 | 2015 | 11 | 0.120 |
Why?
|
| DNA Repair Enzymes | 1 | 2015 | 14 | 0.120 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2017 | 17 | 0.110 |
Why?
|
| Hypesthesia | 2 | 2015 | 9 | 0.110 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2015 | 5 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 64 | 0.110 |
Why?
|
| Indans | 1 | 2015 | 31 | 0.110 |
Why?
|
| Carmustine | 1 | 2015 | 11 | 0.110 |
Why?
|
| Sarcoma | 1 | 2016 | 92 | 0.110 |
Why?
|
| Cyclooxygenase 2 | 1 | 2015 | 51 | 0.110 |
Why?
|
| Lung | 1 | 2016 | 263 | 0.110 |
Why?
|
| Stereotaxic Techniques | 1 | 2014 | 23 | 0.110 |
Why?
|
| Prevalence | 2 | 2014 | 955 | 0.110 |
Why?
|
| Neurosurgical Procedures | 1 | 2015 | 94 | 0.110 |
Why?
|
| Piperidines | 1 | 2015 | 137 | 0.100 |
Why?
|
| Brain Stem | 1 | 2014 | 22 | 0.100 |
Why?
|
| Uveal Neoplasms | 1 | 2014 | 25 | 0.100 |
Why?
|
| PPAR alpha | 1 | 2014 | 24 | 0.100 |
Why?
|
| Taste | 1 | 2013 | 17 | 0.100 |
Why?
|
| Influenza Vaccines | 1 | 2014 | 82 | 0.100 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2013 | 43 | 0.100 |
Why?
|
| Eye Proteins | 1 | 2013 | 36 | 0.100 |
Why?
|
| Smell | 1 | 2013 | 45 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 191 | 0.100 |
Why?
|
| Macular Degeneration | 1 | 2013 | 25 | 0.090 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 50 | 0.090 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 14 | 0.090 |
Why?
|
| Ramipril | 1 | 2012 | 3 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2013 | 273 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 164 | 0.090 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 104 | 0.090 |
Why?
|
| Neurilemmoma | 1 | 2012 | 17 | 0.090 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2012 | 37 | 0.090 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2012 | 4 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2012 | 28 | 0.090 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 199 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 133 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2013 | 243 | 0.090 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 73 | 0.090 |
Why?
|
| Facial Paralysis | 1 | 2011 | 6 | 0.090 |
Why?
|
| Age Factors | 2 | 2013 | 1179 | 0.090 |
Why?
|
| Hydrocephalus | 1 | 2011 | 11 | 0.090 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 36 | 0.080 |
Why?
|
| Cerebral Cortex | 1 | 2012 | 143 | 0.080 |
Why?
|
| Trigeminal Nerve | 1 | 2010 | 5 | 0.080 |
Why?
|
| Craniopharyngioma | 1 | 2010 | 7 | 0.080 |
Why?
|
| Pituitary Neoplasms | 1 | 2010 | 15 | 0.080 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2010 | 44 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 32 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2011 | 149 | 0.080 |
Why?
|
| Cell Membrane | 1 | 2010 | 109 | 0.080 |
Why?
|
| United States | 1 | 2018 | 4072 | 0.080 |
Why?
|
| Sarcoma, Myeloid | 1 | 2009 | 4 | 0.080 |
Why?
|
| North Carolina | 1 | 2013 | 1300 | 0.080 |
Why?
|
| Cognition | 1 | 2014 | 547 | 0.080 |
Why?
|
| Heart Neoplasms | 1 | 2009 | 19 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 114 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 196 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2010 | 193 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2009 | 211 | 0.070 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2007 | 2 | 0.060 |
Why?
|
| Radiodermatitis | 1 | 2006 | 6 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 70 | 0.060 |
Why?
|
| Rhabdoid Tumor | 1 | 2006 | 2 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2006 | 57 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2006 | 48 | 0.060 |
Why?
|
| Cell Separation | 1 | 2007 | 89 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2007 | 184 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 2018 | 73 | 0.060 |
Why?
|
| Teratoma | 1 | 2006 | 9 | 0.060 |
Why?
|
| Transplantation, Heterologous | 2 | 2018 | 109 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 315 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 545 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2015 | 299 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2014 | 553 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 2 | 2013 | 34 | 0.050 |
Why?
|
| Palliative Care | 2 | 2017 | 51 | 0.050 |
Why?
|
| Cerebral Angiography | 2 | 2012 | 60 | 0.040 |
Why?
|
| Amygdala | 2 | 1999 | 60 | 0.040 |
Why?
|
| Body Weight | 2 | 2014 | 323 | 0.040 |
Why?
|
| Anilides | 1 | 2020 | 12 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 21 | 0.040 |
Why?
|
| Chemokine CCL20 | 1 | 2020 | 6 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2020 | 23 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2020 | 32 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 24 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2020 | 66 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2020 | 27 | 0.040 |
Why?
|
| Hippocampus | 2 | 1999 | 216 | 0.040 |
Why?
|
| Pyridines | 1 | 2020 | 79 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2020 | 77 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 90 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 85 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 77 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 106 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 90 | 0.040 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2019 | 20 | 0.040 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2019 | 18 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 146 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 883 | 0.040 |
Why?
|
| HMGA2 Protein | 1 | 2019 | 10 | 0.040 |
Why?
|
| Astrocytes | 1 | 2019 | 61 | 0.040 |
Why?
|
| Down Syndrome | 1 | 1999 | 15 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 65 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 61 | 0.040 |
Why?
|
| Rats | 2 | 2014 | 1895 | 0.040 |
Why?
|
| Limbic System | 1 | 1998 | 15 | 0.040 |
Why?
|
| Biometry | 1 | 1998 | 14 | 0.040 |
Why?
|
| Mediastinum | 1 | 2018 | 14 | 0.040 |
Why?
|
| Temporal Lobe | 1 | 1998 | 34 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2018 | 46 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 131 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 193 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 308 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 252 | 0.030 |
Why?
|
| Cell Movement | 1 | 2018 | 167 | 0.030 |
Why?
|
| Models, Biological | 1 | 2019 | 408 | 0.030 |
Why?
|
| Topotecan | 1 | 2016 | 14 | 0.030 |
Why?
|
| Observer Variation | 2 | 2011 | 96 | 0.030 |
Why?
|
| Dementia | 1 | 1999 | 246 | 0.030 |
Why?
|
| Stilbenes | 1 | 2016 | 20 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2016 | 100 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 1083 | 0.030 |
Why?
|
| Receptors, CCR7 | 1 | 2015 | 4 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2016 | 91 | 0.030 |
Why?
|
| Vaccines, Subunit | 1 | 2014 | 4 | 0.030 |
Why?
|
| Poly I-C | 1 | 2014 | 4 | 0.030 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2015 | 37 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 504 | 0.030 |
Why?
|
| Polylysine | 1 | 2014 | 5 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2015 | 52 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 2014 | 27 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 160 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 246 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 757 | 0.030 |
Why?
|
| Reoperation | 1 | 2015 | 252 | 0.030 |
Why?
|
| Learning | 1 | 2015 | 84 | 0.030 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2014 | 21 | 0.030 |
Why?
|
| Influenza B virus | 1 | 2014 | 19 | 0.030 |
Why?
|
| Vision, Low | 1 | 2014 | 4 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2014 | 99 | 0.030 |
Why?
|
| Pain | 1 | 2015 | 304 | 0.020 |
Why?
|
| Memory | 1 | 2015 | 202 | 0.020 |
Why?
|
| Microsomes | 1 | 2013 | 12 | 0.020 |
Why?
|
| Retina | 1 | 2014 | 86 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2013 | 24 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2013 | 27 | 0.020 |
Why?
|
| Hela Cells | 1 | 2013 | 72 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 506 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 68 | 0.020 |
Why?
|
| Spin Labels | 1 | 2012 | 17 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2012 | 12 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2014 | 299 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2012 | 38 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2012 | 151 | 0.020 |
Why?
|
| Radiometry | 1 | 2012 | 52 | 0.020 |
Why?
|
| Motor Activity | 1 | 2014 | 332 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 104 | 0.020 |
Why?
|
| Otitis Media | 1 | 2011 | 24 | 0.020 |
Why?
|
| Pons | 1 | 2010 | 7 | 0.020 |
Why?
|
| Spinal Nerve Roots | 1 | 2010 | 12 | 0.020 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2010 | 5 | 0.020 |
Why?
|
| Mutation | 1 | 2013 | 497 | 0.020 |
Why?
|
| Ceramides | 1 | 2010 | 10 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2010 | 20 | 0.020 |
Why?
|
| Angiotensin I | 1 | 2012 | 237 | 0.020 |
Why?
|
| Cell Death | 1 | 2010 | 79 | 0.020 |
Why?
|
| Medical Records | 1 | 2010 | 75 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 138 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 556 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 287 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 113 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 288 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2009 | 68 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 757 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 245 | 0.020 |
Why?
|
| Apoptosis | 1 | 2010 | 375 | 0.020 |
Why?
|
| Miniaturization | 1 | 2007 | 5 | 0.020 |
Why?
|
| Computer Systems | 1 | 2007 | 15 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2007 | 44 | 0.020 |
Why?
|
| Myositis | 1 | 2006 | 10 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2007 | 63 | 0.020 |
Why?
|
| Equipment Design | 1 | 2007 | 178 | 0.020 |
Why?
|
| Atrophy | 1 | 1999 | 46 | 0.010 |
Why?
|
| Entorhinal Cortex | 1 | 1998 | 1 | 0.010 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 1998 | 19 | 0.010 |
Why?
|
| Comorbidity | 1 | 1999 | 565 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 1999 | 1479 | 0.010 |
Why?
|